Extensive analysis of the HIV‐1 lifecycle has resulted in the identification of several drug targets, namely, 1) viral entry (entry inhibitors [EI] such as Fusion Inhibitors and CCR5 coreceptor antagonists); 2) viral replication (Nucleoside Reverse Transcriptase Inhibitors [NRTIs] and non‐NRTIs [NNRTIs]); 3) viral integration (Integrase inhibitors) and 4) viral processing (Protease Inhibitors [PIs]).